TABLE 2.
In vitro activity of cefepime-taniborbactam and comparator agents against 1,265 isolates of Enterobacterales with molecularly identified β-lactamase genotypes
| Genotype (no. of isolates; % of total molecularly characterized isolates) | Antimicrobial agent | MIC (μg/mL) |
MIC interpretation |
||||
|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | MIC range | Susceptible (%) | Intermediate (%) | Resistant (%) | ||
| Carbapenemase positive (633; 50.0)c | Cefepime-taniborbactama | 1 | 16 | 0.016 to >16 | 94.6 | NAb | 5.4 |
| Ceftazidime-avibactam | 4 | >16 | ≤0.12 to >16 | 59.6 | NA | 40.4 | |
| Ceftolozane-tazobactam | >8 | >8 | ≤0.25 to >8 | 0.9 | 2.1 | 97.0 | |
| Meropenem-vaborbactam | 8 | >16 | ≤0.06 to >16 | 45.2 | 7.0 | 47.9 | |
| Piperacillin-tazobactam | >128 | >128 | ≤4 to >128 | 0.5 | 2.2 | 97.3 | |
| ESBL positive (534; 42.2)d | Cefepime-taniborbactam | 0.12 | 1 | 0.016 to >16 | 98.7 | NA | 1.3 |
| Ceftazidime-avibactam | 0.25 | 1 | ≤0.12 to >16 | 98.5 | NA | 1.5 | |
| Ceftolozane-tazobactam | 1 | >8 | ≤0.25 to >8 | 77.3 | 5.4 | 17.2 | |
| Meropenem-vaborbactam | ≤0.06 | 0.12 | ≤0.06–16 | 99.6 | 0.2 | 0.2 | |
| Piperacillin-tazobactam | 8 | >128 | ≤4 to >128 | 74.3 | 10.5 | 15.2 | |
| CTX-M-1 positive (393; 31.1) | Cefepime-taniborbactam | 0.12 | 1 | 0.016 to 8 | 100 | NA | 0 |
| Ceftazidime-avibactam | 0.25 | 1 | ≤0.12 to >16 | 99.0 | NA | 1.0 | |
| Ceftolozane-tazobactam | 1 | >8 | ≤0.25 to >8 | 78.6 | 5.1 | 16.3 | |
| Meropenem-vaborbactam | ≤0.06 | 0.12 | ≤0.06 to 8 | 99.7 | 0.3 | 0 | |
| Piperacillin-tazobactam | 8 | >128 | ≤4 to >128 | 73.3 | 12.7 | 14.0 | |
| MBL positive (235; 18.6)e | Cefepime-taniborbactam | 1 | >16 | 0.03 to >16 | 86.4 | NA | 13.6 |
| Ceftazidime-avibactam | >16 | >16 | 0.25 to >16 | 0.9 | NA | 99.2 | |
| Ceftolozane-tazobactam | >8 | >8 | >8 | 0 | 0 | 100 | |
| Meropenem-vaborbactam | >16 | >16 | 0.25 to >16 | 8.9 | 8.1 | 83.0 | |
| Piperacillin-tazobactam | >128 | >128 | ≤4 to >128 | 1.3 | 3.0 | 95.7 | |
| KPC positive (230; 18.2)f | Cefepime-taniborbactam | 0.5 | 4 | 0.016 to 8 | 100 | NA | 0 |
| Ceftazidime-avibactam | 2 | 8 | ≤0.012 to >16 | 93.9 | NA | 6.1 | |
| Ceftolozane-tazobactam | >8 | >8 | 2 to >8 | 0.4 | 2.6 | 97.0 | |
| Meropenem-vaborbactam | ≤0.06 | 2 | ≤0.06 to >16 | 93.5 | 4.8 | 1.7 | |
| Piperacillin-tazobactam | >128 | >128 | 32 to >128 | 0 | 2.6 | 97.4 | |
| NDM positive (207; 16.4)g | Cefepime-taniborbactam | 2 | >16 | 0.12 to >16 | 84.6 | NA | 15.4 |
| Ceftazidime-avibactam | >16 | >16 | 0.25 to >16 | 0.5 | NA | 99.5 | |
| Ceftolozane-tazobactam | >8 | >8 | >8 | 0 | 0 | 100 | |
| Meropenem-vaborbactam | >16 | >16 | 4 to >16 | 3.4 | 7.7 | 88.9 | |
| Piperacillin-tazobactam | >128 | >128 | 32 to >128 | 0 | 1.9 | 98.1 | |
| OXA-48 group positive (168; 13.3)h | Cefepime-taniborbactam | 2 | 4 | 0.03 to >16 | 98.8 | NA | 1.2 |
| Ceftazidime-avibactam | 1 | 2 | ≤0.12 to >16 | 94.6 | NA | 5.4 | |
| Ceftolozane-tazobactam | >8 | >8 | ≤0.25 to >8 | 3.0 | 4.2 | 92.9 | |
| Meropenem-vaborbactam | 16 | >16 | 0.25 to >16 | 29.8 | 8.3 | 61.9 | |
| Piperacillin-tazobactam | >128 | >128 | 64 to >128 | 0 | 0.6 | 99.4 | |
| CTX-M-9 positive (73; 5.8) | Cefepime-taniborbactam | 0.06 | 0.12 | 0.016 to 4 | 100 | NA | 0 |
| Ceftazidime-avibactam | ≤0.12 | 0.25 | ≤0.12 to 0.5 | 100 | NA | 0 | |
| Ceftolozane-tazobactam | 0.5 | 1 | ≤0.25 to 2 | 100 | 0 | 0 | |
| Meropenem-vaborbactam | ≤0.06 | ≤0.06 | ≤0.06 to 0.12 | 100 | 0 | 0 | |
| Piperacillin-tazobactam | ≤4 | 8 | ≤4 to 16 | 100 | 0 | 0 | |
| Acquired AmpC positive (34; 2.7)i | Cefepime-taniborbactam | 0.06 | 2 | 0.016 to 2 | 100 | NA | 0 |
| Ceftazidime-avibactam | 0.25 | 2 | ≤0.12 to >16 | 94.1 | NA | 5.9 | |
| Ceftolozane-tazobactam | 2 | >8 | ≤0.25 to >8 | 58.8 | 8.8 | 32.4 | |
| Meropenem-vaborbactam | ≤0.06 | 0.25 | ≤0.06 to 4 | 100 | 0 | 0 | |
| Piperacillin-tazobactam | 8 | >128 | ≤4 to >128 | 79.4 | 5.9 | 14.7 | |
| SHV ESBL positive (23; 1.8) | Cefepime-taniborbactam | 0.06 | 0.25 | 0.03 to 1 | 100 | NA | 0 |
| Ceftazidime-avibactam | 0.5 | 2 | ≤0.12 to 4 | 100 | NA | 0 | |
| Ceftolozane-tazobactam | 1 | >8 | ≤0.25 to >8 | 73.9 | 4.4 | 21.7 | |
| Meropenem-vaborbactam | ≤0.06 | 0.12 | ≤0.06 to 0.12 | 100 | 0 | 0 | |
| Piperacillin-tazobactam | 8 | >128 | ≤4 to >128 | 73.9 | 4.4 | 21.7 | |
| VIM positive (22; 1.7)j | Cefepime-taniborbactam | 1 | 8 | 0.03 to 16 | 100 | NA | 0 |
| Ceftazidime-avibactam | >16 | >16 | 4 to >16 | 4.6 | NA | 95.5 | |
| Ceftolozane-tazobactam | >8 | >8 | >8 | 0 | 0 | 100 | |
| Meropenem-vaborbactam | 4 | >16 | 0.5 to >16 | 50.0 | 4.6 | 45.5 | |
| Piperacillin-tazobactam | >128 | >128 | 32 to >128 | 0 | 4.6 | 95.5 | |
For comparative purposes only, percent susceptible and percent resistant for cefepime-taniborbactam correspond to the percentage of isolates inhibited at ≤16 μg/mL and ≥32 μg/mL, respectively.
NA, not applicable.
Includes isolates with MBLs and serine carbapenemases; isolates could also possess OSBLs (original spectrum β-lactamases, e.g., TEM-1, SHV-1, etc.), ESBLs, or AmpC-type enzymes.
Isolates could also possess AmpC-type enzymes, or OSBLs, but no carbapenemases.
Includes isolates that possess IMP (n = 5), NDM (n = 207), and VIM (n = 22). One isolate possessed both NDM and IMP.
Isolates could also possess the OXA-48 group, ESBLs, AmpC-type enzymes, OSBLs but not MBLs.
Isolates could also possess serine carbapenemases, ESBLs, AmpCs, and/or OSBLs, but no other MBLs.
Isolates could also possess ESBLs, AmpC-type enzymes, or OSBLs, but no other carbapenemases.
Isolates could also possess OSBLs, but no ESBLs or carbapenemases.
Isolates could also possess serine carbapenemases, ESBLs, AmpCs, and/or OSBLs, but no other MBLs.